Hematological Malignancies

What about ABVD needs improving?

• Bleomycin lung toxicity with ABVD • Efficacy of ABVD is decreased in certain subgroups − In patients with stage III/IV disease, the 5-year FFS is about 65% − In patients >60 years, the 5-year FFS is poor − In patients with IPS 3-7, the 5-year FFS is about 65% • Long-term tumour control of 70% not good enough Improve efficacy!